Format

Send to

Choose Destination
Indian J Clin Biochem. 2005 Jan;20(1):87-94. doi: 10.1007/BF02893049.

Interaction of LDL and platelets in ischaemic and ischaemic risk subjects.

Author information

1
5721 San Diego Street, 94530 El Cerrito, CA USA.

Abstract

Platelets play a vital role in the progression of atherosclerosis and thrombosis, a major cause of death worldwide. Platelets are activated by many triggers like elevated LDL in blood resulting in aggregation and formation of plaque. The purpose of this study was to investigate the effect of LDL and signal transduction inhibitor on the activation of platelets in Ischaemic risk subjects. Platelets from IHD and hyperlipidemic subjects were hypersensitive to ADP, as higher levels of platelet aggregation were observed in these groups. LDL from IHD hyperlipidemic subjects was more effective in activating platelets from any other group. Ox-LDL was more effective in activating platelets than native-LDL as monitored by level of platelet aggregation induced by PAF and thrombin. Calcium channel blocker, nifedipine and verapamil inhibited platelet aggregation at micromolar level. Protein kinase inhibitor, staurosporine was effective in inhibiting ADP induced aggregation at nanomolar level.

KEYWORDS:

Calcium; LDL; Platelet; Platelet aggregation; ox-LDL

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center